# A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme

Source: https://onco.cc/trials/nct05714839/  
OnCo record `nct05714839` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Belantamab mafodotin, Pomalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, now recruiting.

## Summary

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments is a phase 1/2 interventional study registered as NCT05714839 by GlaxoSmithKline, with 123 participants planned, started 2023-06-14 and due to reach its primary completion in 2028-08-03. Interventions recorded: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05714839
- Phase: 1/2
- Setting: A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma
- Sponsor: GlaxoSmithKline
- Enrolled: 123

## Sources

- ClinicalTrials.gov NCT05714839: https://clinicaltrials.gov/study/NCT05714839

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct05714839.json